Engineering stem cells to make mucopolysaccharidosis IIIB
Award amount
$224,469Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Phoenix Nest Inc.
- Proposal award date
- 2016-02-15
- Contract end date
- 2017-06-30
- UEI
- C43HHASBLCV6
- Solicitation number
- PA14-072
- Topic code
- 107
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients.
- Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C
- Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients
- Development and validation of therapy for mucopolysaccharidosis III
- Structure based optimization of a novel pharmacological chaperone therapy for MPSIIIC
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity
- A Digital Biomarker for ALS - Pison Neural Biosensor
- Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
- Development of a novel oral brain penetrant therapeutic for ALS disease
- Engineering a Middle Meningeal Artery Embolization Model with Hydrophilicity and Hydraulic Resistance
Research funding history
8 SBIR/STTR records share this UEI (2014–2024). Reported award amounts total $16,235,847. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services